← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV14행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
ADCStandard DatabasestaleApproved
disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Gemcitabine)
RemeGen·Radical Cystectomy
6 trials
Overview
Program
Disitamab Vedotin and Gemcitabine
Overview
Company
RemeGen
Overview
Modality
ADC
Overview
Target
Radical Cystectomy
Overview
Indication
Radical Cystectomy; Urothelial Carcinoma
Overview
Phase
APPROVED
Overview
Status
ACTIVE
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Established
Overview
Approval status
Approved (flag incomplete)
Toxicology
Major finding
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.. Human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate monotherapy has shown preliminary clinical efficacy in patients with chemotherapy-refractory HER2-positive locally advanced or metastatic urothelial cancer. Previous data showed promising antitumor activity and safety of HER2-specific d…
Clinical
Safety signal
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.. Human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate monotherapy has shown preliminary clinical efficacy in patients with chemotherapy-refractory HER2-positive locally advanced or metastatic urothelial cancer. Previous data showed promising antitumor activity and safety of HER2-specific d…
Clinical
Program phase
APPROVED